-transparent.png){kind=logo}
Six patients with biopsy-documented focal segmental glomerulosclerosis were treated with cyclosporine A (CyA) a new and potent T-cell suppressant. Dosage was adjusted to maintain trough levels between 100 and 300 ng/ml (whole blood radioimmunoassay). Patients were treated for 6 weeks or until unacceptable drug toxicity occurred. In one patient proteinuria was significantly reduced. This same individual was the only patient treated within 6 months of diagnosis. Therapy was discontinued in two patients at week 4, one because of worsening renal failure and one because of hypertension. These complications occurred despite trough CyA blood levels of less than 300 ng/ml. The results suggest that further and controlled studies of CyA are warranted in the therapy of nephrotic syndrome associated with focal segmental glomerulosclerosis, especially when used early in the course of disease. The data also suggest enhanced toxicity of CyA in patients with active nephrotic syndrome.
F B Waldo, and
E C Kohaut
April 2009,
Pediatric nephrology (Berlin, Germany),
F B Waldo, and
E C Kohaut
April 1995,
Journal of the American Society of Nephrology : JASN,
F B Waldo, and
E C Kohaut
March 2003,
Seminars in nephrology,
F B Waldo, and
E C Kohaut
January 1996,
Srpski arhiv za celokupno lekarstvo,
F B Waldo, and
E C Kohaut
August 2017,
Current medical research and opinion,
F B Waldo, and
E C Kohaut
July 2003,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
F B Waldo, and
E C Kohaut
January 2016,
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,
F B Waldo, and
E C Kohaut
March 2016,
Pediatrics international : official journal of the Japan Pediatric Society,
F B Waldo, and
E C Kohaut
February 1993,
Transplantation proceedings,
F B Waldo, and
E C Kohaut
January 1985,
Klinicheskaia meditsina,
